Articles From: Megola Inc. - Megola Product Used in City of Toronto New Parklets to MELA Sciences, a Leader in the Fight Against Melanoma, Appoints Tony Dimun to Its Board of Directors


http://media.marketwire.com/attachments/200802/408449_MGOA_logo_pr.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1070054&ProfileId=051205&sourceType=1 MISSISSAUGA, ON --
Sign-up for Megola Inc. - Megola Product Used in City of Toronto New Parklets investment picks
http://media.marketwire.com/attachments/200802/408449_MGOA_logo_pr.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1069549&ProfileId=051205&sourceType=1 MISSISSAUGA, ON --
Sign-up for Megola Inc. Appointment of David Williams to Senior Advisor and Consultant to Company investment picks
http://media.marketwire.com/attachments/200802/408449_MGOA_logo_pr.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1069103&ProfileId=051205&sourceType=1 MISSISSAUGA, ON --
Sign-up for Megola Inc. Completes Restructuring and Announces New Board of Directors and Plans for the Coming Year investment picks
2013/9/10
Acquisition Expands Pipeline of Drug Candidates, Footprint in Hematologic Cancers SAN DIEGO , Sept.
Sign-up for MEI Pharma Acquires PWT143, A Highly Selective PI3-Kinase Delta Inhibitor investment picks
2014/4/8
SAN DIEGO , April 8, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP) , an oncology company focused on the clinical development of novel therapies for cancer, announced today the appointment of David Urso as Senior Vice President of Corporate Development and General Counsel.
Sign-up for MEI Pharma Adds Former VC David Urso as Senior Vice President of Corporate Development and General Counsel investment picks
SAN DIEGO , Oct.
Sign-up for MEI Pharma Announces Pricing of Public Offering of Common Stock investment picks
SAN DIEGO , Oct.
Sign-up for MEI Pharma Announces Public Offering Of Common Stock investment picks
Tumor Response Observed in Patient with Refractory Small Cell Lung Cancer SAN DIEGO , Oct.
Sign-up for MEI Pharma Announces Topline Data From Phase I Clinical Trial Of Mitochondrial Inhibitor Drug Candidate ME-344 investment picks
2013/9/5
Live Webcast from Boston on Wednesday, September 11 SAN DIEGO , Sept.
Sign-up for MEI Pharma CEO to Present at Stifel Healthcare Conference investment picks
Live Webcast from New York on Tuesday, August 13 SAN DIEGO , Aug.
Sign-up for MEI Pharma CEO To Present At Wedbush Life Sciences Management Access Conference investment picks
2014/4/7
New Pre-Clinical Data Presented at AACR Annual Meeting in San Diego SAN DIEGO , April 7, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP) , an oncology company focused on the clinical development of novel therapies for cancer, announced the presentation of new pre-clinical data showing the ability of its lead drug candidate Pracinostat to inhibit bladder cancer cell growth and induce activated transcription factor 3 (ATF-3) expression, a potential marker of tumor response.
Sign-up for MEI Pharma Identifies Potential Biomarker For Pracinostat In Bladder Cancer investment picks
2014/1/14
Data from Three Ongoing Phase II Trials of Pracinostat Anticipated by Year End SAN DIEGO , Jan.
Sign-up for MEI Pharma Initiates Phase II Clinical Trial Of Pracinostat In Refractory Myelodysplastic Syndrome investment picks
2013/12/5
Live Webcast from New York on Wednesday, December 11th SAN DIEGO , Dec.
Sign-up for MEI Pharma To Host Analyst And Investor Day investment picks
2013/11/26
Live Webcast from New Orleans on Thursday, December 5th SAN DIEGO , Nov.
Sign-up for MEI Pharma To Host Annual Meeting Of Stockholders investment picks
Live Webcast from New York on Friday, September 27 SAN DIEGO , Sept.
Sign-up for MEI Pharma to Present at BioCentury's NewsMakers in the Biotech Industry Conference investment picks
2014/2/25
Live Webcasts from Boston on March 4th and Laguna Niguel on March 10th SAN DIEGO , Feb.
Sign-up for MEI Pharma To Present At Cowen Health Care And ROTH Conferences investment picks
2014/4/1
Live Webcast from New York on Tuesday, April 8th SAN DIEGO , April 1, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP) , an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P.
Sign-up for MEI Pharma To Present At Needham Healthcare Conference investment picks
2013/10/21
Extension of Progression-Free Survival Observed Compared to Last Prior Therapy SAN DIEGO , Oct.
Sign-up for MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Preliminary Evidence of Single-Agent Activity in First-in-Human Clinical Study investment picks
Leading insurance company utilizing technology to win the hearts of customers.
Sign-up for Meiji Yasuda Life Insurance to provide 30,000 Fujitsu tablets with Windows 8 to its sales personnel in Japan's largest deployment investment picks
2014/3/17
MELA Sciences, Inc. (NASDAQ:MELA), (the “Company”), developer of MelaFind ® , an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced financial results for the fourth quarter and year ended December 31, 2013.
Sign-up for MELA Sciences Announces 2013 Fourth Quarter and Year-End Financial Results investment picks
2014/1/22
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind ® , an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced the results of its third company-sponsored Clinical Advisory meeting hosted during the Winter Clinical Dermatology Conference in Hawaii where technical advancements of MelaFind ® and future technology development opportunities were discussed and user’s validated its clinical use.
Sign-up for MELA Sciences Announces the Results of its Third Clinical Advisory Meeting and the Four Clinical Posters Presented at the Winter Clinical Dermatology Conference investment picks
2014/1/2
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind ® , an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced a realignment of its Board’s composition and size to better support the Company’s refocused go-to-market strategy for MelaFind.
Sign-up for MELA Sciences Appoints Healthcare Executive Jeff O’Donnell as Director and Streamlines Board to Support Refocused Go-to-Market Strategy investment picks
2014/2/5
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind ® , an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced the closing of its previously announced $12.45 million private placement of convertible preferred stock, common stock warrants and common stock.
Sign-up for MELA Sciences Completes Private Placement to Institutional Investors and MELA Sciences Directors investment picks
2013/12/9
MELA Sciences, Inc. (NASDAQ: MELA) designer and developer of MelaFind ® , an FDA approved non-invasive optical device that assists dermatologists in the diagnosis of melanoma, received positive dermatologist feedback from its second Clinical Advisory Meeting held in conjunction with the 16th Annual Mount Sinai Winter Dermatology Symposium last week.
Sign-up for MELA Sciences Reports Positive Reception for its Optical Melanoma Diagnostic Device at Clinical Advisory Meeting and Mount Sinai Winter Dermatology Symposium investment picks
2013/11/6
IRVINGTON, N.Y., Nov.
Sign-up for MELA Sciences, a Leader in Melanoma Diagnostics, Reports Third Quarter 2013 Results and Launch of New Strategic Plan investment picks
2013/9/30
IRVINGTON, N.Y., Sept.
Sign-up for MELA Sciences, a Leader in the Fight Against Melanoma, Appoints Tony Dimun to Its Board of Directors investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Megola Inc. - Megola Product Used in City of Toronto New Parklets to MELA Sciences, a Leader in the Fight Against Melanoma, Appoints Tony Dimun to Its Board of Directors
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity